alexa Combination Therapy with Dietary Zeaxanthin for Neovascular Age Related Macular Degeneration. A Randomized Clinical Trial | OMICS International| Abstract
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Clin Exp Ophthalmol 2017, Vol 8(5): 692
  • DOI: 10.4172/2155-9570.1000692

Combination Therapy with Dietary Zeaxanthin for Neovascular Age Related Macular Degeneration. A Randomized Clinical Trial

R Joseph Olk1, Enrique Peralta1, Dennis L Gierhart2, Melissa M Brown3,4 and Gary C Brown3,4*
1The Retina Center, St. Louis County, , St. Louis, Missouri, USA
2Zea Vision, Crown Industrial Court, , Chesterfield, Missouri, USA
3Center for Value-Based Medicine®, Hilton Head, SC, Wills Eye Hospital, Jefferson Medical University, Philadelphia, Pennsylvania, USA
4Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA
*Corresponding Author : Gary C Brown, Center for Value-Based Medicine®, Hilton Head, SC, Wills Eye Hospital, Jefferson Medical University, Philadelphia, Pennsylvania, USA, Tel: +2153536248, Email: [email protected]

Received Date: Oct 31, 2017 / Accepted Date: Nov 16, 2017 / Published Date: Nov 21, 2017

Abstract

Purpose: A previous comparative interventional study suggested oral zeaxanthin added to triple therapy of intravitreal bevacizumab, intravitreal corticosteroids and photodynamic therapy with verteporfin for the treatment of neovascular age-related macular degeneration (NVAMD) was comparatively effective and cost-effective. A randomized clinical trial was undertaken to confirm these effects.

Methodology: A two-year, triple-blinded, randomized clinical trial enrolled 144 participants (168 eyes) with NVAMD to triple therapy (TT) (intravitreal bevacizumab, reduced-fluence photodynamic therapy and intravitreal dexamethasone) or the same triple therapy with oral zeaxanthin (TTZ) supplementation, 20 mg daily. Data were modeled out to the 11-year life expectancy of the average participant.

Results: At 24-months, twenty-seven percent (17/62) of TTZ eyes gained ≥ 15 letters, versus 9% (7/81) of TT eyes (p=0.003). Among unilateral, NVAMD participants, NVAMD developed in 23% (12/53) of TT and 6% (3/47) of TTZ fellow eyes with atrophic age-related macular degeneration (AMD) (p=0.02) by 24 months after baseline. The incremental costutility ratio of oral zeaxanthin supplementation was a remarkably low $30/QALY (quality-adjusted life-year). Zeaxanthin supplementation to TT is cost-effective in every country since the 11-year cost of TTZ ($14,486) exceeds the cost of TT ($14,480) by only $6, yet provides a 0.200 QALY gain.

Conclusion: Oral zeaxanthin supplementation of triple therapy for the treatment of neovascular age-related macular degeneration is comparatively effective because it yields improved vision and reduces the incidence of subsequent neovascular age-related macular degeneration in fellow eyes with atrophic age-related macular degeneration by 74%. Oral zeaxanthin supplementation is very cost-effective in the U.S. and worldwide referent to most ophthalmic interventions.

Keywords: Triple therapy; Neovascular age-related macular degeneration; Zeaxanthin

Citation: Olk RJ, Peralta E, Gierhart DL, Brown MM, Brown GC (2017) Combination Therapy with Dietary Zeaxanthin for Neovascular Age-Related Macular Degeneration. A Randomized Clinical Trial. J Clin Exp Ophthalmol 8: 692. Doi: 10.4172/2155-9570.1000692

Copyright: ©2017 Olk RJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top